The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The research presented herein confirms the correct identification of FRS2 (UniProt: Q8WU20) in Homo sapiens. FRS2, also known as FGFR-signaling adaptor SNT (Suc1-associated neurotrophic factor target 1 or SNT-1), is an approximately 80 kDa membrane-associated adaptor protein containing a phosphotyrosine-binding (PTB) domain and functioning as a critical scaffold downstream of fibroblast growth factor receptors (klimaschewski2021fibroblastgrowthfactor pages 2-4, pennacchietti2025thefoldingand pages 1-6). This description matches the UniProt annotation for Q8WU20.
FRS2 functions as a lipid-anchored signaling scaffold that couples activated receptor tyrosine kinases—principally FGFRs—to intracellular signaling cascades (ferguson2021fibroblastgrowthfactor pages 3-5, klimaschewski2021fibroblastgrowthfactor pages 2-4). Unlike enzymes with catalytic activity, FRS2 organizes multiprotein signaling complexes through its phosphorylation-dependent binding sites, thereby serving as a central organizing platform for signal transduction rather than performing enzymatic substrate conversion (li2018pharmacologicallytargetingthe pages 12-14, tome2023fibroblastgrowthfactor pages 2-4).
FRS2 possesses a modular domain architecture optimized for membrane localization, receptor binding, and effector recruitment. The protein's structural organization is summarized in the table below:
| Domain/Feature | Location | Function | Key References |
|---|---|---|---|
| N-terminal myristoylation motif | Extreme N terminus; includes Gly2 within an MGXXXS/T consensus motif | Covalent N-myristoylation promotes anchoring of FRS2α to the cytoplasmic face of the plasma membrane, positioning it beside FGFR juxtamembrane regions. A non-myristoylatable G2A mutant shows impaired membrane localization, receptor-induced tyrosine phosphorylation, GRB2/SHP2 association, and downstream AKT–ERK signaling. | (li2018pharmacologicallytargetingthe pages 1-2, li2018pharmacologicallytargetingthe pages 3-4, li2018pharmacologicallytargetingthe pages 2-3) |
| PTB (phosphotyrosine-binding) domain | N-terminal structured region following the membrane-targeting sequence | Provides the principal receptor-binding interface. It recognizes non-phosphorylated FGFR juxtamembrane sequences, enabling constitutive receptor association, and can also recognize phosphorylated NPXY-containing peptides from receptors such as TRKA, TRKB, and RET. This domain therefore couples membrane receptors to the FRS2 signaling scaffold and is a candidate site for direct small-molecule inhibition. | (ferguson2021fibroblastgrowthfactor pages 2-3, pennacchietti2025thefoldingand pages 1-6, pennacchietti2025thefoldingand pages 6-10, kumar2023discoveryofa pages 14-15, kumar2023discoveryofa pages 1-2) |
| C-terminal intrinsically disordered tail with tyrosine-phosphorylation sites | Extended C-terminal region, approximately 400 amino acids | FGFR-mediated phosphorylation converts this tail into a multivalent docking platform. Phosphotyrosines recruit PTPN11/SHP2 and GRB2—Y346 is reported as an SHP2-binding site, whereas Y196, Y306, Y349, and Y392 contribute to GRB2-associated complexes—thereby linking receptors to GRB2–SOS–RAS–MAPK and GAB1–PI3K–AKT signaling. The tail also integrates negative feedback through ERK-dependent threonine phosphorylation and CBL-associated ubiquitination. | (ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 5-7, szybowska2021negativeregulationof pages 10-11, pennacchietti2025thefoldingand pages 6-10) |
| Cys61–Cys80 disulfide bridge within the PTB domain | Between Cys61 and Cys80 in the PTB-domain fold | Emerging structural and biophysical evidence indicates that this intradomain bridge stabilizes the native PTB structure and reshapes its folding and ligand-recognition energy landscape. Reduction lowers unfolding free energy by approximately 3 kcal/mol, shifts the unfolding midpoint from about 2.5 M to 0.9 M guanidinium chloride, and markedly weakens FGFR1-peptide affinity, suggesting possible redox-sensitive regulation. Because these findings are recent and derive from biochemical PTB-domain studies, their physiological relevance in intact human cells remains to be established. | (pennacchietti2025thefoldingand pages 79-85, pennacchietti2025thefoldingand pages 34-42, pennacchietti2025thefoldingand pages 75-79, pennacchietti2025thefoldingand pages 28-34) |
Table: This table links the principal structural features of human FRS2 to receptor binding, membrane localization, downstream effector recruitment, and emerging redox-sensitive regulation. It distinguishes established cellular mechanisms from recent PTB-domain biophysical findings.
N-terminal myristoylation: FRS2α contains an MGXXXS/T consensus motif at its extreme N-terminus, with glycine-2 serving as the myristoylation site (li2018pharmacologicallytargetingthe pages 1-2). N-myristoyltransferase catalyzes the covalent attachment of a 14-carbon myristate group, which anchors FRS2 to the cytoplasmic face of the plasma membrane (li2018pharmacologicallytargetingthe pages 12-14, li2018pharmacologicallytargetingthe pages 1-2). This modification is functionally essential: non-myristoylatable G2A mutants show impaired membrane association, reduced tyrosine phosphorylation, and loss of downstream signaling through AKT and MAPK pathways (li2018pharmacologicallytargetingthe pages 1-2, li2018pharmacologicallytargetingthe pages 3-4).
PTB (phosphotyrosine-binding) domain: The centrally located PTB domain mediates the constitutive association of FRS2 with the juxtamembrane region of FGFRs (ferguson2021fibroblastgrowthfactor pages 2-3, pennacchietti2025thefoldingand pages 6-10). This domain exhibits versatile ligand-recognition properties: it binds non-phosphorylated FGFR juxtamembrane sequences as well as phosphorylated NPXY-containing peptides from other receptor tyrosine kinases including TrkA, TrkB, and RET (pennacchietti2025thefoldingand pages 6-10). The PTB domain contains seven β-strands arranged in a β-sandwich architecture with a C-terminal α-helix, characteristic of type I PTB domains (pennacchietti2025thefoldingand pages 1-6).
Recent structural discoveries (2023–2025): A functionally significant disulfide bridge between Cys61 and Cys80 within the PTB domain has been characterized through biophysical folding studies (pennacchietti2025thefoldingand pages 79-85, pennacchietti2025thefoldingand pages 34-42). Under reducing conditions, disruption of this bridge lowers the unfolding free energy by approximately 3 kcal/mol, shifts the unfolding midpoint from ~2.5 M to ~0.9 M guanidinium chloride, and markedly reduces FGFR1 peptide-binding affinity (pennacchietti2025thefoldingand pages 79-85, pennacchietti2025thefoldingand pages 34-42). These findings suggest potential redox-sensitive regulation of FRS2 function, though the physiological relevance in intact cells remains to be established (pennacchietti2025thefoldingand pages 79-85).
C-terminal intrinsically disordered tail: The extended C-terminal region (~400 amino acids) contains multiple tyrosine phosphorylation sites that serve as docking motifs for downstream signaling proteins (pennacchietti2025thefoldingand pages 6-10). Following FGFR activation, specific tyrosine residues are phosphorylated: Y346 recruits PTPN11/SHP2, while Y196, Y306, Y349, and Y392 contribute to GRB2-associated signaling complexes (ferguson2021fibroblastgrowthfactor pages 3-5). This multivalent phosphorylation pattern enables assembly of distinct signaling modules and integration of feedback regulation.
FRS2 carries out its signaling function at the cytoplasmic face of the plasma membrane. The N-terminal myristoylation motif anchors the protein to membrane lipids, positioning it in proximity to transmembrane FGFRs (li2018pharmacologicallytargetingthe pages 1-2, li2018pharmacologicallytargetingthe pages 12-14). FRS2 constitutively associates with the juxtamembrane region of FGFR1 and other FGFR family members, establishing a pre-assembled signaling platform at the membrane that can be rapidly activated upon ligand binding (klimaschewski2021fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 2-3). This membrane-proximal localization is essential for efficient signal propagation: disruption of myristoylation shifts FRS2 toward the cytosol and impairs its signaling function (li2018pharmacologicallytargetingthe pages 1-2, li2018pharmacologicallytargetingthe pages 3-4).
FRS2 serves as the principal adaptor organizing two major signaling cascades downstream of activated FGFRs: the RAS–MAPK/ERK pathway and the PI3K–AKT pathway. A comprehensive summary is provided below:
| Pathway Name | Key Protein Interactions | Biological Outcomes | Regulatory Mechanisms |
|---|---|---|---|
| RAS–MAPK/ERK | Activated FGFR phosphorylates membrane-associated FRS2; phosphotyrosines recruit GRB2–SOS directly and SHP2/PTPN11, which further supports GRB2 recruitment. The resulting complex activates RAS → RAF → MEK → ERK1/2. (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5) | Mitogenic and developmental transcription, cell proliferation, differentiation, migration, and neuronal development. (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5) | ERK1/2 phosphorylates eight FRS2 threonines, reducing FRS2 tyrosine phosphorylation and signaling. SPRY1/2/4 inhibit GRB2–SOS recruitment or downstream RAF activity; DUSP6/MKP3 dephosphorylates ERK. (ferguson2021fibroblastgrowthfactor pages 5-7, szybowska2021negativeregulationof pages 10-11, szybowska2021negativeregulationof pages 8-10) |
| PI3K–AKT | FRS2-bound GRB2 recruits GAB1; phosphorylated GAB1 recruits PI3K, leading to AKT activation. (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5) | Promotes cell survival and anti-apoptotic signaling; contributes to growth, angiogenesis, and oncogenic signaling. (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5) | CBL-dependent turnover of receptor-associated complexes and PI3K attenuates signaling; receptor endocytosis and degradation limit pathway duration. (ferguson2021fibroblastgrowthfactor pages 5-7, tome2023fibroblastgrowthfactor pages 4-6) |
| Neurotrophin/TRK signaling | The FRS2 PTB domain can recognize phosphorylated NPXY-containing peptides from TrkA/TrkB; FRS2/FRS3 adapters connect neurotrophin receptors to intracellular signaling, although dependence is cell- and context-specific. (klimaschewski2021fibroblastgrowthfactor pages 2-4, furusho2020developmentalstage‐specificrole pages 12-13, pennacchietti2025thefoldingand pages 6-10) | Supports dentate-granule-cell maturation, dendritogenesis, excitatory synaptogenesis, and selected forms of neural plasticity; some TrkB outputs remain FRS-independent. (nandi2018neurotrophinandfgf pages 13-16, nandi2018neurotrophinandfgf pages 9-13) | Regulation is context dependent, with functional redundancy between FRS2 and FRS3 and alternative TRK effectors reducing exclusive dependence on FRS2. (furusho2020developmentalstage‐specificrole pages 12-13, nandi2018neurotrophinandfgf pages 9-13) |
| Negative-feedback regulation | CBL is recruited to phosphorylated FRS2–GRB2 complexes and ubiquitinates FRS2 and FGFR; SPRY proteins sequester GRB2 or SOS and inhibit RAS–MAPK signaling; ERK1/2 feeds back directly onto FRS2. (ferguson2021fibroblastgrowthfactor pages 5-7, tome2023fibroblastgrowthfactor pages 4-6, szybowska2021negativeregulationof pages 8-10, szybowska2021negativeregulationof pages 7-8) | Restricts FGFR-signal amplitude and duration, promotes receptor/adaptor internalization or degradation, and prevents sustained proliferative signaling. (ferguson2021fibroblastgrowthfactor pages 5-7, tome2023fibroblastgrowthfactor pages 4-6, klimaschewski2021fibroblastgrowthfactor pages 2-4) | Eight-threonine phosphorylation of FRS2 by ERK1/2; CBL-mediated ubiquitination and lysosomal/proteasomal routing; SPRY-, SPRED-, SEF-, DUSP6-, and phosphatase-mediated inhibition at receptor, adaptor, RAS, RAF, or ERK levels. (ferguson2021fibroblastgrowthfactor pages 5-7, szybowska2021negativeregulationof pages 10-11, szybowska2021negativeregulationof pages 8-10, szybowska2021negativeregulationof pages 7-8) |
Table: This table summarizes the principal pathways organized by FRS2, their molecular interaction partners, biological outputs, and major feedback controls. It distinguishes direct FRS2-dependent signaling from broader, context-dependent regulation.
Upon FGF-induced FGFR dimerization and autophosphorylation, the receptor tyrosine kinase phosphorylates membrane-associated FRS2 on multiple tyrosine residues (klimaschewski2021fibroblastgrowthfactor pages 2-4, tome2023fibroblastgrowthfactor pages 2-4). Phosphorylated FRS2 then recruits the adaptor protein GRB2 and the guanine-nucleotide exchange factor SOS, forming an FRS2α–GRB2–SOS complex that activates RAS GTPase (tome2023fibroblastgrowthfactor pages 2-4, klimaschewski2021fibroblastgrowthfactor pages 2-4). Activated RAS propagates signals through the RAF→MEK→ERK1/2 kinase cascade, ultimately driving transcriptional responses mediated by AP1, Ets, and GATA transcription factors (tome2023fibroblastgrowthfactor pages 2-4). This pathway is critical for FGF-induced proliferation, differentiation, and developmental gene expression (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5).
FRS2 also recruits the protein tyrosine phosphatase PTPN11/SHP2, which becomes phosphorylated and further facilitates GRB2 recruitment, thereby amplifying MAPK signaling (ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 23-24, szybowska2021negativeregulationof pages 7-8). Additional complexes involving CRK/CRKL contribute to sustained ERK1/2 activation downstream of the FGFR–FRS2 signaling node (ferguson2021fibroblastgrowthfactor pages 3-5, ferguson2021fibroblastgrowthfactor pages 5-7).
FRS2-bound GRB2 recruits the scaffolding adaptor GAB1, which upon phosphorylation serves as a docking site for the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5). PI3K activation generates phosphatidylinositol (3,4,5)-trisphosphate, leading to AKT serine/threonine kinase activation and downstream anti-apoptotic and survival signaling (tome2023fibroblastgrowthfactor pages 2-4). This pathway supports cell survival, metabolic reprogramming, and angiogenesis, with particular importance in FGF-mediated vascular development and oncogenic transformation (ferguson2021fibroblastgrowthfactor pages 3-5).
Beyond FGFRs, FRS2 participates in neurotrophin receptor (Trk) signaling pathways. The FRS2 PTB domain recognizes phosphorylated NPXY-containing sequences from TrkA and TrkB receptors, enabling FRS2 to transmit neurotrophin signals in specific cellular contexts (klimaschewski2021fibroblastgrowthfactor pages 2-4, pennacchietti2025thefoldingand pages 6-10). Studies in oligodendrocyte-lineage cells and hippocampal neurons demonstrate that FRS2, often in cooperation with the related adaptor FRS3, mediates TrkB-dependent signaling required for neural development and synaptic plasticity (furusho2020developmentalstage‐specificrole pages 12-13, nandi2018neurotrophinandfgf pages 13-16, nandi2018neurotrophinandfgf pages 9-13). However, TrkB signaling exhibits context-dependent reliance on FRS2: some TrkB outputs remain intact in FRS2/FRS3-deficient cells, indicating alternative or compensatory signaling mechanisms (furusho2020developmentalstage‐specificrole pages 12-13, nandi2018neurotrophinandfgf pages 9-13).
FRS2-dependent signaling is tightly controlled by multiple negative-regulatory mechanisms that limit signal amplitude, duration, and pathway crosstalk (ferguson2021fibroblastgrowthfactor pages 5-7, klimaschewski2021fibroblastgrowthfactor pages 2-4).
ERK-mediated feedback phosphorylation: Activated ERK1/2 phosphorylates FRS2 on eight threonine residues, creating a negative-feedback loop that reduces FRS2 tyrosine phosphorylation and attenuates FGFR–FRS2 signaling (ferguson2021fibroblastgrowthfactor pages 5-7, szybowska2021negativeregulationof pages 10-11). Mutation of these threonine sites results in constitutive FRS2 tyrosine phosphorylation and enhanced signaling, demonstrating the functional importance of this inhibitory mechanism (szybowska2021negativeregulationof pages 10-11).
CBL-mediated ubiquitination: The E3 ubiquitin ligase CBL is recruited to phosphorylated FRS2–GRB2 complexes and ubiquitinates both FRS2 and FGFR, promoting receptor internalization and degradation via lysosomal or proteasomal pathways (ferguson2021fibroblastgrowthfactor pages 5-7, tome2023fibroblastgrowthfactor pages 4-6, szybowska2021negativeregulationof pages 7-8). This CBL-dependent turnover directly limits FRS2-dependent signaling and contributes to signal termination (tome2023fibroblastgrowthfactor pages 4-6).
SPRY and SPRED family inhibitors: SPRY (Sprouty) proteins translocate to the plasma membrane upon FGF stimulation, become phosphorylated, and sequester GRB2 or SOS away from FRS2, thereby suppressing RAS–MAPK activation (ferguson2021fibroblastgrowthfactor pages 5-7, szybowska2021negativeregulationof pages 8-10). SPRED proteins recruit neurofibromin to accelerate RAS-GTP hydrolysis and can promote FGFR degradation through NBR1 (szybowska2021negativeregulationof pages 10-11, szybowska2021negativeregulationof pages 8-10). Additional negative regulators include DUSP6/MKP3 phosphatases that dephosphorylate ERK, GRB14 that blocks PLCγ recruitment, and receptor-proximal inhibitors such as SEF and PTPRG phosphatase (ferguson2021fibroblastgrowthfactor pages 5-7, szybowska2021negativeregulationof pages 10-11, szybowska2021negativeregulationof pages 7-8).
FRS2-mediated FGFR signaling regulates diverse developmental and homeostatic processes across multiple tissues and developmental stages:
| Biological Process | Cell Type/Tissue | Developmental Stage | Key Findings |
|---|---|---|---|
| Oligodendrocyte progenitor specification | Embryonic forebrain/telencephalon; oligodendrocyte-lineage cells | Embryonic development, including approximately E12.5 in mouse studies | FRS2 is a critical mediator of FGFR1 signaling: loss of FRS2 or disruption of FGFR1–FRS2 coupling severely reduces PDGFRA- and OLIG2-positive oligodendrocyte progenitor cells, demonstrating a strong requirement for early lineage specification (furusho2020developmentalstage‐specificrole pages 11-12, furusho2020developmentalstage‐specificrole pages 4-5). |
| Myelination and myelin-sheath growth | Mature oligodendrocytes in the central nervous system | Postnatal active myelination | Unlike its essential early role, FRS2—together with FRS3—is largely dispensable for FGFR2-dependent myelin growth; FRS2/3 disruption produces only minor changes in myelin-gene expression and sheath thickness, indicating that FGFR2 and TrkB also use other effectors in mature oligodendrocytes (furusho2020developmentalstage‐specificrole pages 12-13, furusho2020developmentalstage‐specificrole pages 11-12). |
| Hippocampal neurogenesis and neuronal maturation | Dentate-gyrus neural stem cells and dentate granule cells | Postnatal brain development | Combined FRS2/FRS3 loss impairs dentate-gyrus formation, neural-stem-cell maintenance or proliferation, and granule-cell maturation. Because major abnormalities occur mainly in double mutants, these results support overlapping or compensatory FRS2 and FRS3 functions rather than an exclusively FRS2-specific effect (nandi2018neurotrophinandfgf pages 9-13, nandi2018neurotrophinandfgf pages 13-16). |
| Dendritogenesis and excitatory synaptogenesis | Hippocampal dentate granule cells | Postnatal neuronal maturation | FRS2/FRS3-dependent signaling supports dendritic complexity, dendrite length, spine formation, and functional excitatory synapses. Double mutants exhibit lower spine density and reduced miniature excitatory postsynaptic-current frequency without corresponding changes in amplitude or paired-pulse ratio (nandi2018neurotrophinandfgf pages 9-13, nandi2018neurotrophinandfgf pages 13-16). |
| Cell proliferation and survival | Broadly distributed FGF-responsive cells, including neural precursors | Development and adult tissue homeostasis | Phosphorylated FRS2 recruits GRB2–SOS to activate RAS–RAF–MEK–ERK-dependent mitogenic transcription and recruits GAB1-linked PI3K–AKT signaling that promotes survival and suppresses apoptosis (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5). |
| Cancer invasion, proliferation, and tumor progression | FGFR-dependent cancer models, including ovarian cancer, prostate tumor models, breast and gastric cancer cells, medulloblastoma, and FRS2-amplified liposarcoma | Adult pathological state | Aberrant FGFR–FRS2 signaling supports proliferation, migration, matrix invasion, and tumor growth. Preclinical disruption of the FRS2 PTB-domain interaction or N-terminal myristoylation reduces FRS2/ERK/AKT signaling and tumor phenotypes; however, direct FRS2 ligands remain low-affinity research compounds, and FRS2 amplification alone may not reliably predict response to FGFR inhibitors (li2018pharmacologicallytargetingthe pages 3-4, kumar2023discoveryofa pages 14-15, kumar2023discoveryofa pages 1-2, napolitano2021fibroblastgrowthfactor pages 5-7). |
Table: This table summarizes experimentally supported roles of FRS2 in neural development, intracellular growth and survival signaling, and cancer. It distinguishes FRS2-specific evidence from findings based on combined FRS2/FRS3 perturbation and preclinical disease models.
Oligodendrocyte specification: FRS2 is critically required for embryonic specification of oligodendrocyte progenitor cells (OPCs) downstream of FGFR1. Genetic disruption of FGFR1–FRS2 coupling nearly abolishes PDGFRA+ and OLIG2+ OPC generation in the embryonic telencephalon, demonstrating a non-redundant requirement for FRS2 in early oligodendrocyte-lineage development (furusho2020developmentalstage‐specificrole pages 11-12, furusho2020developmentalstage‐specificrole pages 4-5).
Myelination: In contrast to its essential embryonic role, FRS2 (together with FRS3) is largely dispensable for postnatal myelin growth and gene expression in mature oligodendrocytes. FGFR2-dependent myelination requires additional effectors beyond FRS2/FRS3, suggesting developmental stage-specific adaptor usage (furusho2020developmentalstage‐specificrole pages 11-12).
Hippocampal neurogenesis and synaptogenesis: Combined loss of FRS2 and FRS3 impairs dentate gyrus formation, neural stem-cell maintenance, and granule-cell maturation (nandi2018neurotrophinandfgf pages 9-13, nandi2018neurotrophinandfgf pages 13-16). FRS2/FRS3-dependent signaling supports dendritogenesis, dendritic complexity, spine formation, and excitatory synaptogenesis, as evidenced by reduced spine density and miniature excitatory postsynaptic current frequency in double-mutant neurons (nandi2018neurotrophinandfgf pages 9-13, nandi2018neurotrophinandfgf pages 13-16).
Through activation of RAS–MAPK and PI3K–AKT pathways, FRS2 promotes mitogenic transcription, cell-cycle progression, anti-apoptotic signaling, and cell migration (tome2023fibroblastgrowthfactor pages 2-4, ferguson2021fibroblastgrowthfactor pages 3-5). These functions are essential during tissue development, regeneration, and wound healing, but become pathological when dysregulated in cancer (ferguson2021fibroblastgrowthfactor pages 3-5).
Recent structural studies have advanced understanding of FRS2 PTB-domain folding mechanisms and ligand recognition. Pennacchietti and colleagues (2025) characterized the Cys61–Cys80 disulfide bridge and demonstrated that this feature stabilizes the PTB-domain fold, influences the folding pathway through a three-state mechanism involving a folding intermediate, and modulates ligand-binding kinetics (pennacchietti2025thefoldingand pages 79-85, pennacchietti2025thefoldingand pages 34-42, pennacchietti2025thefoldingand pages 75-79). The binding of TrkB and FGFR1 peptides involves distinct kinetic mechanisms, with electrostatic interactions playing central roles throughout the recognition process (pennacchietti2025thefoldingand pages 79-85). These findings suggest opportunities for redox-sensitive regulation and inform structure-based inhibitor design.
FRS2 has emerged as a potential therapeutic target in FGFR-driven cancers. Two complementary strategies have been explored:
Myristoylation inhibition: Li and colleagues (2018) demonstrated that pharmacological inhibition of N-myristoyltransferase with the myristoyl-CoA analog B13 reduces FRS2α myristoylation and phosphorylation, suppresses FGF/FGFR-mediated signaling (including from drug-resistant FGFR mutants), and inhibits tumor growth in xenograft models without evident organ toxicity (li2018pharmacologicallytargetingthe pages 3-4, li2018pharmacologicallytargetingthe pages 2-3, li2018pharmacologicallytargetingthe pages 1-2). This approach acts downstream of receptor activation and may circumvent kinase-domain mutations that confer resistance to FGFR inhibitors (li2018pharmacologicallytargetingthe pages 3-4).
Direct PTB-domain inhibition: Kumar et al. (2023) used pharmacophore-based virtual screening to identify small-molecule ligands that bind the FRS2 PTB domain and disrupt FGFR–FRS2 coupling (kumar2023discoveryofa pages 14-15, kumar2023discoveryofa pages 1-2). Lead compound 7 showed PTB-domain engagement by thermal-shift and NMR assays, reduced FRS2 Y436 phosphorylation and ERK activation, inhibited collagen invasion and migration in cancer models, and reduced ovarian tumor growth in vivo (kumar2023discoveryofa pages 14-15). However, affinities remain modest (60–140 μM), and proteome-wide profiling identified potential off-targets, indicating that medicinal-chemistry optimization is required before clinical translation (kumar2023discoveryofa pages 14-15).
FRS2 amplification as biomarker: In dedifferentiated liposarcoma, FRS2 gene amplification has been proposed as a marker of FGFR-pathway dependence. However, FRS2 amplification alone may not reliably predict response to FGFR inhibitors; ligand expression and pathway context also influence therapeutic sensitivity (napolitano2021fibroblastgrowthfactor pages 5-7).
Comprehensive reviews published in 2023–2024 have synthesized current understanding of FGFR signaling in cancer (Shan et al., 2024; Marin et al., 2024), nervous system development and disease (Tomé et al., 2023; Klimaschewski & Claus, 2021), and oligodendrocyte biology (Furusho et al., 2020). These works emphasize FRS2's central coordinating role while highlighting pathway complexity, context-dependent regulation, and the challenges of FGFR-targeted therapy (tome2023fibroblastgrowthfactor pages 2-4, klimaschewski2021fibroblastgrowthfactor pages 2-4, furusho2020developmentalstage‐specificrole pages 11-12).
Aberrant FGFR–FRS2 signaling contributes to multiple cancer types through gene amplification, activating mutations, and oncogenic fusions. Preclinical studies support FRS2 as a druggable node that could complement or overcome resistance to FGFR kinase inhibitors (li2018pharmacologicallytargetingthe pages 3-4, kumar2023discoveryofa pages 14-15). Current challenges include improving inhibitor potency and selectivity, identifying robust predictive biomarkers, and validating therapeutic strategies in clinical trials. The stage-specific and context-dependent nature of FRS2 function—demonstrated in oligodendrocyte and neuronal development—suggests that FRS2-targeted therapies may need to account for tissue-specific pathway wiring and compensatory mechanisms (furusho2020developmentalstage‐specificrole pages 11-12, furusho2020developmentalstage‐specificrole pages 12-13).
FRS2 (UniProt: Q8WU20) is a membrane-anchored scaffold protein that functions as the principal adaptor downstream of fibroblast growth factor receptors and participates in neurotrophin receptor signaling. Through its N-terminal myristoylation, PTB domain, and C-terminal phosphorylation sites, FRS2 organizes multiprotein signaling complexes that activate the RAS–MAPK/ERK and PI3K–AKT pathways. FRS2-dependent signaling is essential for embryonic oligodendrocyte specification, supports neurogenesis and synaptogenesis, and regulates cell proliferation and survival. Negative-feedback mechanisms involving ERK phosphorylation, CBL-mediated ubiquitination, and SPRY/SPRED inhibitors tightly control signal amplitude and duration. Recent structural studies (2023–2025) have revealed a functionally important disulfide bridge in the PTB domain, and preclinical therapeutic strategies targeting FRS2 myristoylation or PTB-domain interactions show promise in FGFR-driven cancers. Continued research is needed to translate these mechanistic insights into effective clinical interventions while accounting for the context-dependent and developmental stage-specific functions of this versatile signaling adaptor.
References
(klimaschewski2021fibroblastgrowthfactor pages 2-4): Lars Klimaschewski and Peter Claus. Fibroblast growth factor signalling in the diseased nervous system. Molecular Neurobiology, 58:3884-3902, Apr 2021. URL: https://doi.org/10.1007/s12035-021-02367-0, doi:10.1007/s12035-021-02367-0. This article has 152 citations and is from a peer-reviewed journal.
(pennacchietti2025thefoldingand pages 1-6): V Pennacchietti. The folding and binding mechanisms of the ptb domain of frs2: an unexpected role of a disulfide bridge in rewiring folding and function. Unknown journal, 2025.
(ferguson2021fibroblastgrowthfactor pages 3-5): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.
(li2018pharmacologicallytargetingthe pages 12-14): Qianjin Li, Omar Awad Alsaidan, Yongjie Ma, Sungjin Kim, Junchen Liu, Thomas Albers, Kebin Liu, Zanna Beharry, Shaying Zhao, Fen Wang, Iryna Lebedyeva, and Houjian Cai. Pharmacologically targeting the myristoylation of the scaffold protein frs2α inhibits fgf/fgfr-mediated oncogenic signaling and tumor progression. Journal of Biological Chemistry, 293:6434-6448, Apr 2018. URL: https://doi.org/10.1074/jbc.ra117.000940, doi:10.1074/jbc.ra117.000940. This article has 36 citations and is from a domain leading peer-reviewed journal.
(tome2023fibroblastgrowthfactor pages 2-4): Diogo Tomé, Marta S. Dias, Joana Correia, and Ramiro D. Almeida. Fibroblast growth factor signaling in axons: from development to disease. Cell Communication and Signaling : CCS, Oct 2023. URL: https://doi.org/10.1186/s12964-023-01284-0, doi:10.1186/s12964-023-01284-0. This article has 45 citations.
(li2018pharmacologicallytargetingthe pages 1-2): Qianjin Li, Omar Awad Alsaidan, Yongjie Ma, Sungjin Kim, Junchen Liu, Thomas Albers, Kebin Liu, Zanna Beharry, Shaying Zhao, Fen Wang, Iryna Lebedyeva, and Houjian Cai. Pharmacologically targeting the myristoylation of the scaffold protein frs2α inhibits fgf/fgfr-mediated oncogenic signaling and tumor progression. Journal of Biological Chemistry, 293:6434-6448, Apr 2018. URL: https://doi.org/10.1074/jbc.ra117.000940, doi:10.1074/jbc.ra117.000940. This article has 36 citations and is from a domain leading peer-reviewed journal.
(li2018pharmacologicallytargetingthe pages 3-4): Qianjin Li, Omar Awad Alsaidan, Yongjie Ma, Sungjin Kim, Junchen Liu, Thomas Albers, Kebin Liu, Zanna Beharry, Shaying Zhao, Fen Wang, Iryna Lebedyeva, and Houjian Cai. Pharmacologically targeting the myristoylation of the scaffold protein frs2α inhibits fgf/fgfr-mediated oncogenic signaling and tumor progression. Journal of Biological Chemistry, 293:6434-6448, Apr 2018. URL: https://doi.org/10.1074/jbc.ra117.000940, doi:10.1074/jbc.ra117.000940. This article has 36 citations and is from a domain leading peer-reviewed journal.
(li2018pharmacologicallytargetingthe pages 2-3): Qianjin Li, Omar Awad Alsaidan, Yongjie Ma, Sungjin Kim, Junchen Liu, Thomas Albers, Kebin Liu, Zanna Beharry, Shaying Zhao, Fen Wang, Iryna Lebedyeva, and Houjian Cai. Pharmacologically targeting the myristoylation of the scaffold protein frs2α inhibits fgf/fgfr-mediated oncogenic signaling and tumor progression. Journal of Biological Chemistry, 293:6434-6448, Apr 2018. URL: https://doi.org/10.1074/jbc.ra117.000940, doi:10.1074/jbc.ra117.000940. This article has 36 citations and is from a domain leading peer-reviewed journal.
(ferguson2021fibroblastgrowthfactor pages 2-3): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.
(pennacchietti2025thefoldingand pages 6-10): V Pennacchietti. The folding and binding mechanisms of the ptb domain of frs2: an unexpected role of a disulfide bridge in rewiring folding and function. Unknown journal, 2025.
(kumar2023discoveryofa pages 14-15): Karthiga Santhana Kumar, Cyrill Brunner, Matthias Schuster, Levi Luca Kopp, Alexandre Gries, Shen Yan, Simon Jurt, Kerstin Moehle, Dominique Bruns, Michael Grotzer, Oliver Zerbe, Gisbert Schneider, and Martin Baumgartner. Discovery of a small molecule ligand of frs2 that inhibits invasion and tumor growth. Cellular Oncology (Dordrecht), 46:331-356, Dec 2023. URL: https://doi.org/10.1007/s13402-022-00753-x, doi:10.1007/s13402-022-00753-x. This article has 14 citations.
(kumar2023discoveryofa pages 1-2): Karthiga Santhana Kumar, Cyrill Brunner, Matthias Schuster, Levi Luca Kopp, Alexandre Gries, Shen Yan, Simon Jurt, Kerstin Moehle, Dominique Bruns, Michael Grotzer, Oliver Zerbe, Gisbert Schneider, and Martin Baumgartner. Discovery of a small molecule ligand of frs2 that inhibits invasion and tumor growth. Cellular Oncology (Dordrecht), 46:331-356, Dec 2023. URL: https://doi.org/10.1007/s13402-022-00753-x, doi:10.1007/s13402-022-00753-x. This article has 14 citations.
(ferguson2021fibroblastgrowthfactor pages 5-7): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.
(szybowska2021negativeregulationof pages 10-11): Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Ellen Margrethe Haugsten, and Antoni Wiedlocha. Negative regulation of fgfr (fibroblast growth factor receptor) signaling. Cells, 10:1342, May 2021. URL: https://doi.org/10.3390/cells10061342, doi:10.3390/cells10061342. This article has 67 citations.
(pennacchietti2025thefoldingand pages 79-85): V Pennacchietti. The folding and binding mechanisms of the ptb domain of frs2: an unexpected role of a disulfide bridge in rewiring folding and function. Unknown journal, 2025.
(pennacchietti2025thefoldingand pages 34-42): V Pennacchietti. The folding and binding mechanisms of the ptb domain of frs2: an unexpected role of a disulfide bridge in rewiring folding and function. Unknown journal, 2025.
(pennacchietti2025thefoldingand pages 75-79): V Pennacchietti. The folding and binding mechanisms of the ptb domain of frs2: an unexpected role of a disulfide bridge in rewiring folding and function. Unknown journal, 2025.
(pennacchietti2025thefoldingand pages 28-34): V Pennacchietti. The folding and binding mechanisms of the ptb domain of frs2: an unexpected role of a disulfide bridge in rewiring folding and function. Unknown journal, 2025.
(szybowska2021negativeregulationof pages 8-10): Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Ellen Margrethe Haugsten, and Antoni Wiedlocha. Negative regulation of fgfr (fibroblast growth factor receptor) signaling. Cells, 10:1342, May 2021. URL: https://doi.org/10.3390/cells10061342, doi:10.3390/cells10061342. This article has 67 citations.
(tome2023fibroblastgrowthfactor pages 4-6): Diogo Tomé, Marta S. Dias, Joana Correia, and Ramiro D. Almeida. Fibroblast growth factor signaling in axons: from development to disease. Cell Communication and Signaling : CCS, Oct 2023. URL: https://doi.org/10.1186/s12964-023-01284-0, doi:10.1186/s12964-023-01284-0. This article has 45 citations.
(furusho2020developmentalstage‐specificrole pages 12-13): Miki Furusho, Akihiro Ishii, Jean M. Hebert, and Rashmi Bansal. Developmental stage‐specific role of frs adapters as mediators of fgf receptor signaling in the oligodendrocyte lineage cells. Glia, 68:617-630, Mar 2020. URL: https://doi.org/10.1002/glia.23743, doi:10.1002/glia.23743. This article has 14 citations and is from a domain leading peer-reviewed journal.
(nandi2018neurotrophinandfgf pages 13-16): Sayan Nandi, Karina Alviña, Pablo J. Lituma, Pablo E. Castillo, and Jean M. Hébert. Neurotrophin and fgf signaling adapter proteins, frs2 and frs3, regulate dentate granule cell maturation and excitatory synaptogenesis. Neuroscience, 369:192-201, Jan 2018. URL: https://doi.org/10.1016/j.neuroscience.2017.11.017, doi:10.1016/j.neuroscience.2017.11.017. This article has 12 citations and is from a domain leading peer-reviewed journal.
(nandi2018neurotrophinandfgf pages 9-13): Sayan Nandi, Karina Alviña, Pablo J. Lituma, Pablo E. Castillo, and Jean M. Hébert. Neurotrophin and fgf signaling adapter proteins, frs2 and frs3, regulate dentate granule cell maturation and excitatory synaptogenesis. Neuroscience, 369:192-201, Jan 2018. URL: https://doi.org/10.1016/j.neuroscience.2017.11.017, doi:10.1016/j.neuroscience.2017.11.017. This article has 12 citations and is from a domain leading peer-reviewed journal.
(szybowska2021negativeregulationof pages 7-8): Patrycja Szybowska, Michal Kostas, Jørgen Wesche, Ellen Margrethe Haugsten, and Antoni Wiedlocha. Negative regulation of fgfr (fibroblast growth factor receptor) signaling. Cells, 10:1342, May 2021. URL: https://doi.org/10.3390/cells10061342, doi:10.3390/cells10061342. This article has 67 citations.
(ferguson2021fibroblastgrowthfactor pages 23-24): Harriet R. Ferguson, Michael P. Smith, and Chiara Francavilla. Fibroblast growth factor receptors (fgfrs) and noncanonical partners in cancer signaling. Cells, 10:1201, May 2021. URL: https://doi.org/10.3390/cells10051201, doi:10.3390/cells10051201. This article has 150 citations.
(furusho2020developmentalstage‐specificrole pages 11-12): Miki Furusho, Akihiro Ishii, Jean M. Hebert, and Rashmi Bansal. Developmental stage‐specific role of frs adapters as mediators of fgf receptor signaling in the oligodendrocyte lineage cells. Glia, 68:617-630, Mar 2020. URL: https://doi.org/10.1002/glia.23743, doi:10.1002/glia.23743. This article has 14 citations and is from a domain leading peer-reviewed journal.
(furusho2020developmentalstage‐specificrole pages 4-5): Miki Furusho, Akihiro Ishii, Jean M. Hebert, and Rashmi Bansal. Developmental stage‐specific role of frs adapters as mediators of fgf receptor signaling in the oligodendrocyte lineage cells. Glia, 68:617-630, Mar 2020. URL: https://doi.org/10.1002/glia.23743, doi:10.1002/glia.23743. This article has 14 citations and is from a domain leading peer-reviewed journal.
(napolitano2021fibroblastgrowthfactor pages 5-7): Andrea Napolitano, Alexandra E. Ostler, Robin L. Jones, and Paul H. Huang. Fibroblast growth factor receptor (fgfr) signaling in gist and soft tissue sarcomas. Cells, 10:1533, Jun 2021. URL: https://doi.org/10.3390/cells10061533, doi:10.3390/cells10061533. This article has 41 citations.